Evotec shares collapsed by more than 33 per cent today after the German drug discovery company announced that a late-stage clinical trial for a key neurological treatment had failed to meet its primary efficacy goals. The stock fell from €9.40 at the open to as low as €6.30 by mid-morning, wiping approximately €1.2bn off the company's market capitalisation.
Investors fled the stock after Evotec said the phase III trial did not achieve a statistically significant improvement over placebo in the primary endpoint. The company, which partners with major pharmaceutical firms including Bristol Myers Squibb and Novo Nordisk, has long relied on its pipeline of early-stage and mid-stage assets to justify a premium valuation. Today's news has shattered that narrative.
Analysts at Jefferies responded by slashing their price target from €14 to €6, while downgrading the stock from 'buy' to 'underperform'. In a note to clients, they described the outcome as 'a major blow to the company's credibility and near-term revenue visibility'. The failed drug was considered one of the most advanced wholly-owned assets in Evotec's portfolio.
The sell-off rippled through European biotech indices, with the STOXX Europe 600 Health Care index falling 1.2 per cent. UK-listed peers such as AstraZeneca and Hikma Pharmaceuticals were largely unaffected, but the event has reignited broader caution around small-cap biotech stocks. For UK investors with exposure to European biotech through exchange-traded funds or actively managed funds, the episode underscores the high-risk nature of drug development.
Evotec's management has said it will review the full data set and present findings at an upcoming medical conference. The company has not yet indicated whether it will abandon the programme entirely or attempt to salvage it with a different patient subgroup or dosing regimen. In the meantime, the stock remains under heavy selling pressure, with volumes more than ten times the 30-day average.